Biliary Tract Carcinoma Clinical Trials

7 recruiting

Biliary Tract Carcinoma Trials at a Glance

16 actively recruiting trials for biliary tract carcinoma are listed on ClinicalTrialsFinder across 6 cities in 17 countries. The largest study group is Phase 2 with 12 trials, with the heaviest enrollment activity in St Louis, Jacksonville, and Anderlecht. Lead sponsors running biliary tract carcinoma studies include Mayo Clinic, National Cancer Center, Korea, and Fudan University.

Browse biliary tract carcinoma trials by phase

Treatments under study

About Biliary Tract Carcinoma Clinical Trials

Looking for clinical trials for Biliary Tract Carcinoma? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Biliary Tract Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Biliary Tract Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 116 of 16 trials

Recruiting
Phase 2

Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma

Biliary Tract Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd60 enrolled1 locationNCT07099547
Recruiting
Phase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+41 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting
Phase 1

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Metastatic Biliary Tract CarcinomaMetastatic Biliary Tract Cancer
Washington University School of Medicine48 enrolled1 locationNCT07107750
Recruiting
Phase 2

MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma

Advanced Biliary Tract Carcinoma
Centre Hospitalier Universitaire de Besancon75 enrolled11 locationsNCT07036380
Recruiting
Phase 1Phase 2

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

Breast CancerOvarian CancerEndometrial Cancer+1 more
AstraZeneca460 enrolled67 locationsNCT05123482
Recruiting
Phase 1Phase 2

Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer

Advanced Biliary Tract Carcinoma
Tongji Hospital29 enrolled1 locationNCT07392541
Recruiting
Phase 2

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

CholangiocarcinomaBile Duct CancerBiliary Tract Carcinoma
Nataliya Uboha33 enrolled4 locationsNCT06048133
Recruiting
Phase 2

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

Locally Advanced Hepatocellular CarcinomaLocally Advanced Gastric CarcinomaAdvanced Biliary Tract Carcinoma+7 more
OHSU Knight Cancer Institute66 enrolled1 locationNCT05705492
Recruiting
Phase 2

GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma

Biliary Tract Carcinoma
Fudan University93 enrolled1 locationNCT05668884
Recruiting
Phase 2

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Breast CarcinomaUrothelial CarcinomaOvarian Carcinoma+26 more
Mayo Clinic27 enrolled1 locationNCT07285044
Recruiting
Phase 3

Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients

Biliary Tract CancerAdvanced CancerMetastatic Biliary Tract Carcinoma+2 more
Tata Memorial Centre220 enrolled6 locationsNCT07062263
Recruiting
Not Applicable

Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma

RadiotherapyBiliary Tract CarcinomaRadio-frequency Ablation
National Cancer Center, Korea53 enrolled1 locationNCT06168292
Recruiting
Phase 2

Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers

Unresectable Pancreatic CancerUnresectable Bile Duct CarcinomaUnresectable Biliary Tract Carcinoma
National Cancer Center, Korea98 enrolled1 locationNCT06135896
Recruiting
Phase 2

Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma

Unresectable Biliary Tract Carcinoma
Henan Cancer Hospital63 enrolled1 locationNCT06749730
Recruiting
Not Applicable

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Hepatocellular CarcinomaBiliary Tract CarcinomaColorectal Adenocarcinoma+1 more
Zhejiang Cancer Hospital120 enrolled1 locationNCT06349044
Recruiting
Phase 2

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Metastatic Gastroesophageal Junction Adenocarcinoma+30 more
Northwestern University94 enrolled1 locationNCT05733000